MYC and acute myeloid leukemia: In our study, c-Myc inhibitor 10058-F4 promoted AML cells differentiation through increasing the rate of CD11b positive section and restored cell sensitivity to Ara-C, DNR or Doxo (Figure 5, 6), indicating that inhibition of c-Myc activity could suppress the drug resistance to chemotherapeutics in AML cells by promoting cell differentiation.